stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) EV/FCF
As of 6 November 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a EV/FCF of −97.6×. Over the past ten years it has ranged from −110× (October 2024) to 84.0× (December 2020); the current reading is higher than 2% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −8.1× | — |
| FY2024 | −34.1× | — |
| FY2023 | 14.3× | 338.79% |
| FY2022 | 3.3× | (75.82%) |
| FY2021 | 13.5× | 46.41% |
| FY2020 | 9.2× | (88.65%) |
| FY2019 | 81.3× | 0.00% |
| FY2018 | 81.3× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −99.3× | — |
| Jun 2026 | −28.7× | — |
| Mar 2026 | −9.9× | — |
| Dec 2025 | −8.1× | — |
| 24 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. | −97.6× |
| TRVI Trevi Therapeutics, Inc. compare | −36.2× |
| MAZE Maze Therapeutics, Inc. compare | −15.4× |
| TRAX First Tracks Biotherapeutics, Inc. compare | −13.8× |
| MESO Mesoblast Limited compare | −13.1× |
| VIR Vir Biotechnology, Inc. compare | −11.3× |
| REPL Replimune Group, Inc. compare | −8.5× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 4.6× |
| SRPT Sarepta Therapeutics, Inc. compare | 10.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))